肿瘤化疗止吐药阿瑞匹坦胶囊国内上市

On July 20, 2020, Qilu Pharmaceutical’s Class 4 generic drug Aprepitant Capsules was approved for marketing by the State Food and Drug Administration, which was deemed to have passed the consistency evaluation and was the first generic drug in China. The capsules are indicated for the prevention of acute and delayed nausea and vomiting during initial and repeated treatment with highly emetogenic antineoplastic chemotherapy when administered in combination with other antiemetics.

Neurokinin 1 receptor antagonists (NK-1RA) are a new class of antiemetic drugs that mainly achieve antiemetic effects by combining with the central nervous system and its peripheral NK-1 receptors to block the release of substances. They have the advantages of high selectivity and high affinity. The acute phase CINV is mainly related to the release of 5-hydroxytryptamine (5-HT;), and the delayed CINV is related to the release of substance P. At present, my country's NK-1 drugs mainly include aprepitant (oral dosage form) and fosaprepitant (injection).

Research at home and abroad on the use of aprepitant to prevent CINV in adult patients has been relatively mature. Related studies have found that in adult patients with colorectal cancer, the CR rate of using aprepitant + 5-HT3 receptor antagonist + dexamethasone in combination to prevent CINV caused by oxaliplatin is higher than that of using only 5-HT3 receptor antagonist + Compared with dexamethasone, there was no difference in the rate of acute vomiting (94.7% vs. 92.4%, P=0.37), but there was a significant difference in the rate of delayed and overall vomiting (95.7% vs. 84.7%, P=0.02 ;95.7 vs. 83.6%, P=0.01).

Another study analyzed the efficacy of aprepitant in preventing nausea and vomiting caused by high-dose cisplatin in Chinese adult lung cancer patients (Phase III clinical trial). It was found that the aprepitant group (dexamethasone + granisetron + aprepitant) was better than the control group (dexamethasone + granisetron + placebo) in preventing vomiting. In particular, the difference in the CR rate of delayed vomiting was more obvious between groups (72.7% vs. 59.9%, P=0.019).

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.